Literature DB >> 2673663

Pharmacokinetics of oral cefetamet pivoxil (Ro 15-8075) and intravenous cefetamet (Ro 15-8074) in humans: a review.

K Stoeckel1, Y K Tam, J Kneer.   

Abstract

Cefetamet pivoxil belongs to the class of orally absorbed pro-drug esters which are hydrolyzed to the active compound (cefetamet) on their first pass through the gut wall and/or the liver. The intravenously administered cefetamet is eliminated predominantly unchanged in the urine by glomerular filtration. Systemic and renal clearance values for cefetamet were 140 and 130 ml/min, respectively. The plasma protein binding is 22%, whereby the only binding protein is albumin. The steady state volume of distribution (0.29 l/kg) corresponds roughly to the extracellular water space which is consistent with other low protein-bound cephalosporins. In general, after intravenous doses, cefetamet follows the kinetic behaviour of a cephalosporin with low protein binding, limited non-renal clearance, and renal clearance that is predominantly due to glomerular filtration, e.g. ceftizoxime, ceftazidime. After oral administration, cefetamet pivoxil shows a significant food effect (F = 41% vs 51%). Hence, cefetamet pivoxil is recommended to be taken after food. The food effect, however, is not of such a magnitude that it will be of clinical consequence when this recommendation is not followed. The food effect is not related to a change in gastric pH because antacids and ranitidine do not affect the absorption of cefetamet pivoxil, although in approximately 20% of the subjects absorption of the drug is delayed. The elimination of cefetamet is directly proportional to renal function. In patients with varying degrees of renal insufficiencies, dosage should be decreased accordingly. Age has no effect on the bioavailability of cefetamet pivoxil. However, the clearance of cefetamet is higher in children and lower in the elderly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673663     DOI: 10.1185/03007998909115930

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  9 in total

1.  [Pharmacokinetics of cefixime in volunteers and a literature comparison with the new ester prodrug cephalosporins].

Authors:  F Kees; K G Naber
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 3.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

4.  A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

Authors:  E M Sokal; E A Roberts; G Mieli-Vergani; P McPhillips; M Johnson; J Barber; N Dallow; E Boxall; D Kelly
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Design, synthesis, and evaluation of prodrugs of ertapenem.

Authors:  Sheo B Singh; Diane Rindgen; Prudence Bradley; Lovji Cama; Wanying Sun; Michael J Hafey; Takao Suzuki; Nengxue Wang; Hao Wu; Basheng Zhang; Li Wang; Chongmin Ji; Hongshi Yu; Richard Soll; David B Olsen; Peter T Meinke; Deborah A Nicoll-Griffith
Journal:  ACS Med Chem Lett       Date:  2013-07-03       Impact factor: 4.345

Review 6.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

7.  Pharmacokinetics of loracarbef and interaction with acetylcysteine.

Authors:  S Roller; H Lode; I Stelzer; K M Deppermann; M Boeckh; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 8.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

9.  Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil.

Authors:  N H Holford; R J Ambros; K Stoeckel
Journal:  J Pharmacokinet Biopharm       Date:  1992-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.